Arzerra 1000mg Solution for Infusion

Arzerra 1000mg Solution for Infusion is an anti-cancer medicine used in the treatment of cancer. The intravenous route of this medicine is used in combination with chlorambucil for the treatment of CLL in patients for whom fludarabine-based therapy is considered inappropriate and as an extended treatment in patients who have a partial response after at least two lines of therapy. Chronic lymphocytic leukaemia is a cancer that occurs in the bone marrow and blood. The subcutaneous route of the medicine is used in treating relapsing forms of multiple sclerosis. It is a condition in which the immune system attacks the protective covering of the nerves called myelin.

Arzerra 1000mg Solution for Infusion contains Ofatumumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the B-cell lymphocytes that are responsible for the multiplication of cancer cells.

Arzerra 1000mg Solution for Infusion may cause certain side effects, such as nausea, vomiting, diarrhoea, fever, decreased platelet count, fatigue, cough, insomnia, injection site reactions and pain at the site of injection. If the side effects bother you, inform your doctor. A trained healthcare professional will administer Arzerra 1000mg Solution for Infusion. Hence, do not self-administer.

While taking Arzerra 1000mg Solution for Infusion if you experience any allergic reaction, inform your doctor. Before receiving this injection, inform your doctor if you have any pre-existing or a history of liver/kidney disease, active infections, skin problems, or any allergic conditions. Arzerra 1000mg Solution for Infusion is known to cause fetal B-cell depletion in neonates. Hence, inform your physician if you are pregnant beforehand. Breastfeeding mothers should avoid taking Arzerra 1000mg Solution for Infusion.

Arzerra 1000mg Solution for Infusion contains Ofatumumab, which belongs to the class of CD20-directed cytolytic antibodies. It is used in the treatment of chronic lymphocytic leukaemia. This medicine works by binding to the CD20 antibody and causes lysis of B-cell lymphocytes responsible for the multiplication of cancer cells. This causes shrinkage of tumour cells and thereby prevents the growth and further spread of cancerous or non-cancerous cells.

Arzerra 1000mg Solution for Infusion should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before receiving this injection, inform your doctor if you have any history of liver/kidney disease, active infections, skin problems, or any allergic conditions. Arzerra 1000mg Solution for Infusion may cause remission of active infections, severe skin reactions, tumour lysis syndrome (tumour cells release their contents into the bloodstream), hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, and hypersensitivity reactions in some patients. Hence, careful monitoring should be done during the entire treatment. Arzerra 1000mg Solution for Infusion may cause fetal B-cell depletion in infants. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Before nursing, a breastfeeding mother should ask her oncologist whether this medicine is safe for use or not. Arzerra 1000mg Solution for Infusion is not recommended for use in children as the safety and efficacy are not established.